

Table SI. Illness perception, analysed by Revised Illness Perception Questionnaire (IPQ-R), for 92 patients with primary cutaneous lymphoma

Revised Illness Perception Questionnaire	<i>n</i>	Mean ± standard deviation	Lower border 95% CI	Upper border 95% CI	Min-Max	<i>F</i> (df1, df2)	<i>p</i> -value	Cronbach's α
<i>Timeline acute/chronic</i>								
IA-IIA early	36	20.00 ± 2.757	19.07	20.93	14–25	9.37 (3, 35.30)	<0.001	0.827
IIB-IVB advanced	19	21.42 ± 2.631	20.15	22.69	17–25			
Non-mycosis fungoides (MF)/SS	13	15.62 ± 5.108	12.53	18.70	8–22			
Cutaneous B-cell lymphoma	24	16.33 ± 4.697	14.35	18.32	6–25			
Total	92	18.72 ± 4.285	17.83	19.60	6–25			
<i>Consequences</i>								
IA-IIA early	36	12.11 ± 3.890	10.80	13.43	5–24	2.06 (3, 88)	0.111	0.768
IIB-IVB advanced	19	14.32 ± 4.164	12.31	16.32	7–20			
Non-MF/SS	13	10.92 ± 4.499	8.20	13.64	6–18			
Other cutaneous B-cell lymphoma	24	11.58 ± 4.916	9.51	13.66	5–23			
Total	92	12.26 ± 4.392	11.35	13.17	5–24			
<i>Personal control</i>								
IA-IIA early	36	10.64 ± 3.322	9.51	11.76	4–17	0.68 (3, 88)	0.565	0.761
IIB-IVB advanced	19	9.89 ± 3.053	8.42	11.37	4–17			
Non-MF/SS	13	11.54 ± 3.821	9.23	13.85	4–16			
Cutaneous B-cell lymphoma	24	11.00 ± 3.563	9.50	12.50	6–18			
Total	92	10.71 ± 3.389	10.00	11.41	4–18			
<i>Treatment control</i>								
IA-IIA early	36	13.25 ± 3.102	12.20	14.30	5–18	5.02 (3, 88)	0.003	0.663
IIB-IVB advanced	19	12.00 ± 2.925	10.59	13.41	6–16			
Non-MF/SS	13	12.15 ± 2.478	10.66	13.65	8–16			
Cutaneous B-cell lymphoma	24	15.08 ± 2.717	13.94	16.23	9–20			
Total	92	13.32 ± 3.074	12.68	13.95	5–20			
<i>Coherence</i>								
IA-IIA early	36	14.92 ± 4.332	13.45	16.38	6–24	1.33 (3, 88)	0.269	0.786
IIB-IVB advanced	19	12.68 ± 3.945	10.78	14.59	6–20			
Non-MF/SS	13	13.69 ± 4.715	10.84	16.54	6–21			
Cutaneous B-cell lymphoma	24	14.71 ± 4.027	13.01	16.41	8–22			
Total	92	14.23 ± 4.256	13.35	15.11	6–24			
<i>Timeline cyclical</i>								
IA-IIA early	36	12.36 ± 3.182	11.28	13.44	4–19	4.83 (3, 88)	0.004	0.704
IIB-IVB advanced	19	13.26 ± 2.513	12.05	14.47	7–16			
Non-MF/SS	13	10.85 ± 3.211	8.91	12.79	4–15			
Cutaneous B-cell lymphoma	24	9.92 ± 3.658	8.37	11.46	4–16			
Total	92	11.70 ± 3.393	10.99	12.40	4–19			
<i>Emotional representations</i>								
IA-IIA early	36	14.08 ± 5.531	12.21	15.95	5–25	0.72 (3, 88)	0.544	0.921
IIB-IVB advanced	19	16.37 ± 5.101	13.91	18.83	7–25			
Non-MF/SS	13	14.46 ± 5.301	11.26	17.67	5–25			
Cutaneous B-cell lymphoma	24	14.63 ± 6.156	12.03	17.22	5–25			
Total	92	14.75 ± 5.562	13.60	15.90	5–25			

IA-IIA: early-stage MF; IIB-IVB: advanced-stage MF and Sézary syndrome (SS); non-MF/SS includes cutaneous T-cell lymphoma subtypes other than MF/SS; CI: confidence interval.